<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04516720</url>
  </required_header>
  <id_info>
    <org_study_id>PROICM 2017-01 BNO</org_study_id>
    <nct_id>NCT04516720</nct_id>
  </id_info>
  <brief_title>Creation of a Clinical Database on Primary Nervous System Tumors</brief_title>
  <acronym>BDD-NO</acronym>
  <official_title>Creation of a Clinical Database on Primary Nervous System Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the creation of a clinical database including data for all PCNST patients is of high&#xD;
      interest. This database will allow us to develop clinical studies on:&#xD;
&#xD;
        -  The clinical, radiological and biological presentation of tumors, the impact of&#xD;
           oncological treatments and the evaluation of survival for the different subtypes of&#xD;
           Primary central nervous system tumors (PCNST). This is particularly important for rare&#xD;
           histological subtypes of PCNST for which the current knowledge is scarce;&#xD;
&#xD;
        -  Clinical, radiological and biological factors predictive of tumor response to&#xD;
           treatments;&#xD;
&#xD;
        -  Prognostic factors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary central nervous system tumors (PCNST) correspond to all primitive tumors involving&#xD;
      central nervous system structures, meninges and the origin of the cranial and paraspinal&#xD;
      nerves. They have a malignant, benign, or borderline evolution. TPSNC represent a&#xD;
      heterogeneous group of tumors, with more than 140 subtypes described in the WHO&#xD;
      classification. The causes, prognostic factors, and therapeutic management differ according&#xD;
      to the histological subtype.&#xD;
&#xD;
      The incidence of all of TPSNCs ranges from 17.6 to 22.0/105 in North American and European&#xD;
      studies. However, because of the high number of different histological subtypes, most of them&#xD;
      must be considered as rare tumors. Moreover, they represent a major public health problem due&#xD;
      to high morbidity [8] and mortality.&#xD;
&#xD;
      In this context, the creation of a clinical database including data for all PCNST patients is&#xD;
      of high interest. This database will allow us to develop clinical studies on:&#xD;
&#xD;
        -  The clinical, radiological and biological presentation of tumors, the impact of&#xD;
           oncological treatments and the evaluation of survival for the different subtypes of&#xD;
           PCNST. This is particularly important for rare histological subtypes of PCNST for which&#xD;
           the current knowledge is scarce;&#xD;
&#xD;
        -  Clinical, radiological and biological factors predictive of tumor response to&#xD;
           treatments;&#xD;
&#xD;
        -  Prognostic factors.&#xD;
&#xD;
      The database will also allow us to develop or participate in multicentric clinical studies,&#xD;
      at the national or international level, as well as to facilitate the identification of&#xD;
      patients for inclusion in translational studies&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">January 2028</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Establish an exhaustive database of patients treated for a Primary central nervous system tumors at the Montpellier Cancer Institute, whatever the histological subtype and the oncological treatment</measure>
    <time_frame>From date of inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>collection of clinical data in the medical record</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Realization of clinical studies specific to certain histological subtypes to be carried out on the clinical, radiological and biological presentation of patients, specific oncological treatments and toxicities, prognostic factors and survival data</measure>
    <time_frame>From date of inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>obtaining reliable clinical data for write new clinical trials project</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To allow the realization of epidemiological studies specific to certain histological subtypes</measure>
    <time_frame>From date of inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>new clinical trials project based on this clinical database</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To facilitate the identification of patients for inclusion in French or European retrospective studies</measure>
    <time_frame>From date of inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>new clinical trials project based on this clinical database</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1700</enrollment>
  <condition>Nervous System Tumor</condition>
  <arm_group>
    <arm_group_label>Primary Nervous System Tumors arm</arm_group_label>
    <description>The information letter will be delivered by the investigator physician to the patients to inform them on the study, its implementation and their complete freedom to participate or not.&#xD;
Clinical Data and Questionnaires:&#xD;
For the retrospective part&#xD;
Patient identification based on data from the Medical Information Department (DIM) of the ICM;&#xD;
Verification of the eligibility criteria;&#xD;
Inclusion of patients in a coded form in BDD-NO;&#xD;
Implementation of the database with the data already collected (as an coded EXCEL file) in specific studies (some patients are included in several of these studies): study of diffuse low grade gliomas, study on anaplastic gliomas, study on the place of Bevacizumab in high-grade gliomas, clinical database created&#xD;
Collection of clinical data from each patient's medical record&#xD;
For the prospective part&#xD;
Inclusion of patients in a coded form in BDD-NO;&#xD;
Collection of clinical data from each patient's medical record.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>data collection</intervention_name>
    <description>Diagnostic data : date and description of first symptoms,date of radiological diagnosis, tumor localization, number of lesions, date of histological diagnosis, histological diagnostic mode, histological diagnosis, WHO grade (I, II, III or IV), immunohistochemic data, molecular alterations therapeutic sequence : type of treatment, baseline exam before each treatment, surgery, radiothérapy, systemic treatment, clinical study, follow up until death</description>
    <arm_group_label>Primary Nervous System Tumors arm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        all patient with Primary central nervous system tumors and treated at the Montpellier&#xD;
        Cancer Institute&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient aged ≥ 18, no age limit;&#xD;
&#xD;
          -  Diagnosis of Primary central nervous system tumors ;&#xD;
&#xD;
          -  Patient treated at the Montpellier Cancer Institute, whatever the treatment received&#xD;
             (systemic treatment, radiotherapy or exclusive supportive care);&#xD;
&#xD;
          -  For the retrospective part of the study, patient first treated at the Montpellier&#xD;
             Cancer Institute between January 1rst, 2004 and the beginning of the prospective part;&#xD;
&#xD;
          -  Patient information for the retrospective (patient still alive at the beginning of the&#xD;
             study) and prospective study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary lesions of the central nervous system;&#xD;
&#xD;
          -  Patient not affiliated to a social protection scheme;&#xD;
&#xD;
          -  Subject under tutelage, curatorship or safeguard of justice.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amélie DARLIX, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut régional du Cancer Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Pierre BLEUSE, MD</last_name>
    <phone>04 67 61 31 02</phone>
    <phone_ext>+33</phone_ext>
    <email>DRCI-icm105@icm.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Icm Val D'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <state>Herault</state>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>amelie DARLIX, MD</last_name>
      <phone>04 67 61 25 57</phone>
      <phone_ext>+33</phone_ext>
      <email>amelie.darlix@icm.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Michel FABBRO, MD</last_name>
      <phone>04 67 61 30 63</phone>
      <phone_ext>+33</phone_ext>
      <email>michel.fabbro@icm.unicancer.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007 Aug;114(2):97-109. Epub 2007 Jul 6. Review. Erratum in: Acta Neuropathol. 2007 Nov;114(5):547.</citation>
    <PMID>17618441</PMID>
  </results_reference>
  <results_reference>
    <citation>Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016 Jun;131(6):803-20. doi: 10.1007/s00401-016-1545-1. Epub 2016 May 9. Review.</citation>
    <PMID>27157931</PMID>
  </results_reference>
  <results_reference>
    <citation>Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol. 2015 Oct;17 Suppl 4:iv1-iv62. doi: 10.1093/neuonc/nov189. Epub 2015 Oct 27.</citation>
    <PMID>26511214</PMID>
  </results_reference>
  <results_reference>
    <citation>Wöhrer A, Waldhör T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mösenbacher U, Kiefer A, Maier H, Motz R, Reiner-Concin A, Richling B, Idriceanu C, Scarpatetti M, Sedivy R, Bankl HC, Stiglbauer W, Preusser M, Rössler K, Hainfellner JA. The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol. 2009 Dec;95(3):401-411. doi: 10.1007/s11060-009-9938-9. Epub 2009 Jun 28.</citation>
    <PMID>19562257</PMID>
  </results_reference>
  <results_reference>
    <citation>Baldi I, Gruber A, Alioum A, Berteaud E, Lebailly P, Huchet A, Tourdias T, Kantor G, Maire JP, Vital A, Loiseau H; Gironde TSNC Registry Group. Descriptive epidemiology of CNS tumors in France: results from the Gironde Registry for the period 2000-2007. Neuro Oncol. 2011 Dec;13(12):1370-8. doi: 10.1093/neuonc/nor120. Epub 2011 Oct 6.</citation>
    <PMID>21980160</PMID>
  </results_reference>
  <results_reference>
    <citation>Crocetti E, Trama A, Stiller C, Caldarella A, Soffietti R, Jaal J, Weber DC, Ricardi U, Slowinski J, Brandes A; RARECARE working group. Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer. 2012 Jul;48(10):1532-42. doi: 10.1016/j.ejca.2011.12.013. Epub 2012 Jan 7.</citation>
    <PMID>22227039</PMID>
  </results_reference>
  <results_reference>
    <citation>Darlix A, Zouaoui S, Rigau V, Bessaoud F, Figarella-Branger D, Mathieu-Daudé H, Trétarre B, Bauchet F, Duffau H, Taillandier L, Bauchet L. Epidemiology for primary brain tumors: a nationwide population-based study. J Neurooncol. 2017 Feb;131(3):525-546. doi: 10.1007/s11060-016-2318-3. Epub 2016 Nov 16. Erratum in: J Neurooncol. 2017 Feb;131(3):547.</citation>
    <PMID>27853959</PMID>
  </results_reference>
  <results_reference>
    <citation>DeAngelis LM. Brain tumors. N Engl J Med. 2001 Jan 11;344(2):114-23. Review.</citation>
    <PMID>11150363</PMID>
  </results_reference>
  <results_reference>
    <citation>Jakola AS, Skjulsvik AJ, Myrmel KS, Sjåvik K, Unsgård G, Torp SH, Aaberg K, Berg T, Dai HY, Johnsen K, Kloster R, Solheim O. Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol. 2017 Aug 1;28(8):1942-1948. doi: 10.1093/annonc/mdx230.</citation>
    <PMID>28475680</PMID>
  </results_reference>
  <results_reference>
    <citation>Capelle L, Fontaine D, Mandonnet E, Taillandier L, Golmard JL, Bauchet L, Pallud J, Peruzzi P, Baron MH, Kujas M, Guyotat J, Guillevin R, Frenay M, Taillibert S, Colin P, Rigau V, Vandenbos F, Pinelli C, Duffau H; French Réseau d'Étude des Gliomes. Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article. J Neurosurg. 2013 Jun;118(6):1157-68. doi: 10.3171/2013.1.JNS121. Epub 2013 Mar 15.</citation>
    <PMID>23495881</PMID>
  </results_reference>
  <results_reference>
    <citation>Boetto J, Bertram L, Moulinié G, Herbet G, Moritz-Gasser S, Duffau H. Low Rate of Intraoperative Seizures During Awake Craniotomy in a Prospective Cohort with 374 Supratentorial Brain Lesions: Electrocorticography Is Not Mandatory. World Neurosurg. 2015 Dec;84(6):1838-44. doi: 10.1016/j.wneu.2015.07.075. Epub 2015 Aug 14.</citation>
    <PMID>26283485</PMID>
  </results_reference>
  <results_reference>
    <citation>Mandonnet E, Wager M, Almairac F, Baron MH, Blonski M, Freyschlag CF, Barone F, Fontaine D, Pallud J, Hegi M, Viegas C, Zetterling M, Spena G, Goodden J, Rutten GJ, Taillandier L, Foroglu N, Darlix A, Skrap M, Martino J, von Campe G, Madadaki C, Gayat E, de Witt Hamer P, Gil Robles S, Sarubbo S, Santarius T, Bello L, Forster MT, Duffau H. Survey on current practice within the European Low-Grade Glioma Network: where do we stand and what is the next step? Neurooncol Pract. 2017 Dec;4(4):241-247. doi: 10.1093/nop/npw031. Epub 2017 Jan 17. Erratum in: Neurooncol Pract. 2017 Jun;4(2):136. Santorius, Thomas [corrected to Santarius, Thomas].</citation>
    <PMID>31386020</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary central nervous system tumors</keyword>
  <keyword>clinical database</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

